Risk of Infections with Biological Agents

Uri Kopylov, Waqqas Afif*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


An increasing proportion of patients with inflammatory bowel disease (IBD) are treated with biological medications. The risk of infectious complications remains a significant concern in patients treated with biologics. Treatment with biological agents in IBD is generally safe, but there may be an increased risk of certain opportunistic infections. Some of the infectious risks are class specific, whereas others are a common concern for all biologics. A careful screening, surveillance, and immunization program, in accordance with available guidelines, is important to minimize any risk of infectious complications.

Original languageEnglish
Pages (from-to)509-524
Number of pages16
JournalGastroenterology Clinics of North America
Issue number3
StatePublished - Sep 2014
Externally publishedYes


  • Anti-tumor necrosis factor α
  • Biologics
  • Infection
  • Inflammatory bowel disease
  • Opportunistic infections
  • Vaccinations


Dive into the research topics of 'Risk of Infections with Biological Agents'. Together they form a unique fingerprint.

Cite this